Breaking News Instant updates and real-time market news.

KALV

KalVista

$15.23 /

-0.56 (-3.55%)

07:15
01/13/20
01/13
07:15
01/13/20
07:15

KalVista provides update on oral HAE franchise

KalVista provided an update on its franchise of oral plasma kallikrein inhibitors for treatment of hereditary angioedema, or HAE. In developing the strategy for its oral HAE franchise, KalVista has conducted patient, physician and payer research to identify the key needs in the market. Oral therapy remains the highest unmet need according to all stakeholders, with 93% of patients surveyed by KalVista expressing a willingness to switch to oral therapy for both on-demand and prophylactic usage. However, the survey data shows that patients are not prepared to accept significantly reduced efficacy with a switch to oral therapy. The survey also indicated that twice-daily dosing would have little impact on willingness to switch compared to once-daily. KalVista anticipates that KVD824 can meet the efficacy and safety needs of patients as an oral prophylactic treatment. KVD824 is a highly potent and selective plasma kallikrein inhibitor which achieved high exposures and a favorable safety and tolerability profile in a first-in-human study. KalVista intends to investigate twice-daily dosing in the planned Phase 2 trial to maximize efficacy while maintaining the convenience of an oral therapy.

KALV KalVista
$15.23 /

-0.56 (-3.55%)

08/19/19 CANT
KalVista's 2H could be 'tranformational' for PKal-inhib, says Cantor Fitzgerald
10/14/19 ROTH
Ophthalmic therapies 'could go from 0 to 100 real quick,' says Roth Capital
12/09/19 ROTH
Roth says KalVista trial results have 'silver lining' despite endpoint miss
12/10/19 NEED
KalVista price target lowered to $28 from $35 at Needham

TODAY'S FREE FLY STORIES

Initiation
Oneok initiated with an Outperform at Scotiabank » 05:39
01/28/20
01/28
05:39
01/28/20
05:39
OKE

Oneok

$74.03 /

-0.825 (-1.10%)

Scotiabank analyst Alonso…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Foot Locker downgraded to Market Perform from Outperform at Telsey Advisory » 05:37
01/28/20
01/28
05:37
01/28/20
05:37
FL

Foot Locker

$38.36 /

-0.24 (-0.62%)

Telsey Advisory analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Aimco downgraded to Market Perform from Outperform at BMO Capital » 05:36
01/28/20
01/28
05:36
01/28/20
05:36
AIV

Aimco

$53.62 /

-0.41 (-0.76%)

BMO Capital downgraded…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Essex Property Trust downgraded to Underperform from Market Perform at BMO Capital » 05:36
01/28/20
01/28
05:36
01/28/20
05:36
ESS

Essex Property Trust

$309.25 /

+0.25 (+0.08%)

BMO Capital downgraded…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Hexo downgraded to Neutral from Buy at MKM Partners » 05:35
01/28/20
01/28
05:35
01/28/20
05:35
HEXO

Hexo

$1.33 /

-0.065 (-4.66%)

MKM Partners analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Hexo downgraded to Neutral from Buy at MKM Partners » 05:35
01/28/20
01/28
05:35
01/28/20
05:35
HEXO

Hexo

/

+

MKM Partners analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Canopy Growth upgraded to Outperform from Market Perform at BMO Capital » 05:31
01/28/20
01/28
05:31
01/28/20
05:31
CGC

Canopy Growth

$21.54 /

-1.14 (-5.03%)

BMO Capital analyst Tamy…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Zions Bancorp upgraded to Neutral from Underperform at Baird » 05:30
01/28/20
01/28
05:30
01/28/20
05:30
ZION

Zions Bancorp

$46.47 /

-0.17 (-0.36%)

Baird analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Wells Fargo upgraded to Neutral from Underperform at Baird » 05:30
01/28/20
01/28
05:30
01/28/20
05:30
WFC

Wells Fargo

$47.08 /

-0.5 (-1.05%)

Baird analyst David…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Turkiye Vakiflar upgraded to Hold from Sell at Societe Generale » 05:29
01/28/20
01/28
05:29
01/28/20
05:29
TKYVY

Turkiye Vakiflar

$0.00 /

+ (+0.00%)

Societe Generale analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Upgrade
BAE Systems upgraded to Overweight from Equal Weight at Barclays » 05:26
01/28/20
01/28
05:26
01/28/20
05:26
BAESY

BAE Systems

$0.00 /

+ (+0.00%)

Barclays analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Pacific Drilling downgraded to Hold from Buy at Fearnley » 05:24
01/28/20
01/28
05:24
01/28/20
05:24
PACD

Pacific Drilling

$1.72 /

-0.18 (-9.47%)

Fearnley analyst Truls…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
PulteGroup upgraded to Outperform from In Line at Evercore ISI » 05:23
01/28/20
01/28
05:23
01/28/20
05:23
PHM

PulteGroup

$44.34 /

+0.62 (+1.42%)

Evercore ISI analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Adidas upgraded to Outperform from Market Perform at Telsey Advisory » 05:22
01/28/20
01/28
05:22
01/28/20
05:22
ADDYY

Adidas

$0.00 /

+ (+0.00%)

Telsey Advisory analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Stratasys should be bought on any weakness from outlook, says Piper Sandler » 05:21
01/28/20
01/28
05:21
01/28/20
05:21
SSYS

Stratasys

$19.62 /

-0.45 (-2.24%)

2019 was a disappointing…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Reseller survey shows mixed 3D printing demand in Q4, says Piper Sandler » 05:17
01/28/20
01/28
05:17
01/28/20
05:17
SSYS

Stratasys

$19.62 /

-0.45 (-2.24%)

, DDD

3D Systems

$11.08 /

-0.29 (-2.55%)

Based on feedback from a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Activision Blizzard price target raised to $69 from $62 at Piper Sandler » 05:14
01/28/20
01/28
05:14
01/28/20
05:14
ATVI

Activision Blizzard

$58.32 /

-1.04 (-1.75%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Electronic Arts price target raised to $124 from $106 at Piper Sandler » 05:12
01/28/20
01/28
05:12
01/28/20
05:12
EA

Electronic Arts

$110.62 /

-1.68 (-1.50%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Genpact forms strategic alliance with Amplexor » 05:10
01/28/20
01/28
05:10
01/28/20
05:10
G

Genpact

$43.68 /

-0.66 (-1.49%)

Amplexor and Genpact…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Take-Two price target raised to $141 from $134 at Piper Sandler » 05:10
01/28/20
01/28
05:10
01/28/20
05:10
TTWO

Take-Two

$123.01 /

-2.23 (-1.78%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Regeneron, Sanofi announce FDA Priority Review for Dupixent » 05:08
01/28/20
01/28
05:08
01/28/20
05:08
REGN

Regeneron

$339.50 /

-5.59 (-1.62%)

, SNY

Sanofi

$47.80 /

-0.935 (-1.92%)

Regeneron Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Acceleron price target raised to $135 from $73 at Piper Sandler » 05:08
01/28/20
01/28
05:08
01/28/20
05:08
XLRN

Acceleron

$52.83 /

+0.81 (+1.56%)

Piper Sandler analyst…

Piper Sandler analyst Danielle Brill raised her price target for Acceleron Pharma to $135 from $73 after the Phase 2 proof-of-concept study of sotatercept in pulmonary arterial hypertension met its primary endpoint and key secondary efficacy endpoints. The stock in premarket trading is up 66%, or $35.13, to $88.00. Importantly, the results also met Acceleron's predefined threshold for clinical significance, Brill tells investors in a research note. While few details were provided in the release, the positive findings in this "robust" Phase 2 provides "solid evidence" for sotatercept's role as a disease-modifying agent for pulmonary arterial hypertension, contends the analyst. She reiterates an Overweight rating on Acceleron shares.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Vivint Smart Home downgraded to In-Line from Outperform at Imperial Capital » 05:05
01/28/20
01/28
05:05
01/28/20
05:05
VVNT

Vivint Smart Home

$11.72 /

-0.01 (-0.09%)

Imperial Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
3D Systems downgraded to Neutral from Overweight at Piper Sandler » 05:02
01/28/20
01/28
05:02
01/28/20
05:02
DDD

3D Systems

$11.08 /

-0.29 (-2.55%)

Piper Sandler analyst…

Piper Sandler analyst Troy Jensen downgraded 3D Systems to Neutral from Overweight with an unchanged price target of $12. The shares closed Monday down 30c to $11.08. The analyst sees limited upside from current valuations and limited 2020 catalysts after his Q4 reseller survey indicated "another struggle this quarter" for 3D Systems. However, consensus estimates are "somewhat achievable" as they reflect less than normal seasonality for Q4 and the company appears to be focused on cost cuts to improve profitability, Jensen tells investors in a research note. The analyst, who notes 3D shares have appreciated nearly 30% since the start of the year, says 2020 does not appear to be a big year for new product introductions. He advises investors to wait for pullbacks before getting more constructive on 3D Systems shares.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
PG&E upgraded to Buy from Neutral at Mizuho » 04:59
01/28/20
01/28
04:59
01/28/20
04:59
PCG

PG&E

$14.07 /

-0.205 (-1.44%)

Mizuho analyst Paul…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.